OTC Derivatives and EMIR Refit: What Corporate Investors Must Know

Over-the-counter derivatives — derivative contracts whose execution does not take place on a regulated market or equivalent third-country market for EMIR purposes — are an essential tool for corporate treasuries managing interest rate, FX, and commodity exposures. They are also subject to an extensive regulatory framework in the European Union, and the framework continues to evolve.

IMPORTANT DISCLAIMER. This article is provided for general information and educational purposes only. It does not constitute investment advice, a personal recommendation, an offer or a solicitation to buy or sell any financial instrument, or an offer to provide or  enter into any investment service. Nothing in this article should be relied upon as a forecast, projection, or guarantee of future results. Investing in financial instruments involves risk, including the risk of losing part or all of the capital invested. Past performance is not a reliable indicator of future results, and any performance figures or examples presented in this article are provided for illustrative or historical purposes only and do not guarantee future results. Skanestas Investments Limited is regulated by the Cyprus Securities and Exchange Commission (CySEC) under licence number CIF251/14. Independent professional advice should be sought as needed. Any reference to specific products or services is for general informational purposes only; the provision of investment services and the assessment of appropriateness or suitability, where applicable are subject to the applicable regulatory requirements and the firm’s relevant procedures.

 

The EMIR Refit reporting standards became applicable in April 2024 with significant changes from the previous regime, and EMIR 3 entered into force in late 2024 with further amendments. This article explains what OTC derivatives are, how the EMIR framework classifies counterparties and assigns obligations, what changed under Refit, what EMIR 3 means, and what corporate investors need to know to remain compliant. Independent legal and regulatory advice is appropriate for material exposures. The framing is informational; this article does not constitute investment, legal, or tax advice, and individual circumstances should be assessed with qualified counsel.

 

What an OTC Derivative Is

An over-the-counter derivative is a bilaterally negotiated contract between two parties whose value derives from an underlying asset — interest rates, currencies, commodities, equities, credit. Unlike exchange-traded derivatives, OTC contracts can be customised to specific notional sizes, maturities, and reference rates that meet the parties’ needs. The flexibility is the primary reason corporate users prefer OTC derivatives for many hedging applications: a swap can be sized to match a specific debt issuance, and an FX forward can be tailored to a specific commercial transaction.

The customisation comes with structural consequences. OTC contracts can create  direct counterparty risk between the two parties. There is no central counterparty clearing in the standard form, no daily mark-to-market unless contractually agreed, and no exchange providing surveillance and price discovery. The regulatory framework — EMIR and its successors — is designed to  address these risks through clearing, reporting, and risk-mitigation requirements.

EMIR in Brief

The European Market Infrastructure Regulation (EMIR), Regulation (EU) No 648/2012, came into force in 2012 in response to G20 commitments following the 2008 financial crisis. EMIR has four main pillars: clearing of standardised OTC derivatives through central counterparties, reporting of derivative transactions to trade repositories, risk mitigation for non-cleared OTC derivatives, and prudential requirements for central counterparties.

EMIR has been amended multiple times. The first ‘EMIR Refit’ in 2019 (Regulation 2019/834) made initial adjustments to reduce burden on smaller participants. A second iteration, commonly referred to as ‘EMIR Refit reporting’ or ‘2024 EMIR Refit,’ introduced revised reporting technical standards that became applicable on 29 April 2024. EMIR 3 (the most recent legislative amendment) entered into force in late 2024 with further changes including the Active Account Requirement. The result is a layered regulatory environment in which the operative rules at any given time are a combination of the original EMIR text, multiple subsequent amendments, and a series of regulatory technical standards (RTS) and implementing technical standards (ITS) issued by ESMA.

Counterparty Classifications

EMIR distinguishes between Financial Counterparties (FCs) and Non-Financial Counterparties (NFCs). The classification determines which obligations apply.

Financial Counterparties (FCs)

FCs are, broadly, regulated entities in the financial sector: banks, investment firms, insurance and reinsurance undertakings, certain pension schemes, certain UCITS and their management companies, alternative investment funds and certain AIFMs, and central securities depositories. FCs are further divided into FC+ (those whose group derivative activity exceeds defined clearing thresholds) and FC- (those below the thresholds). FC+ entities are subject to the central clearing obligation for relevant OTC derivative classes.

Non-Financial Counterparties (NFCs)

NFCs are corporate entities that are not financial counterparties — typically commercial corporates using derivatives for hedging or treasury purposes. NFCs are also divided based on activity: NFC+ entities are those whose relevant derivative activity exceeds the applicable  clearing thresholds (calculated separately for each asset class). NFC- entities are below the thresholds. The classification matters because NFC+ entities are subject to the clearing obligation for relevant OTC derivative classes; NFC- entities are not.

Hedging derivatives can typically be excluded from the threshold calculation for NFCs, which is why many commercial corporates qualify as NFC- despite using derivatives meaningfully — the use is dominantly for hedging commercial exposures rather than speculative purposes. The exclusion applies to transactions that meet the relevant EMIR hedging criteria; it does not mean that all derivatives described by a corporate as “hedging” are automatically excluded.

What EMIR Refit (2024) Changed in Reporting

The reporting changes that became applicable on 29 April 2024 are the most operationally significant element of recent EMIR amendments. Key changes include:

ISO 20022 XML Format

Reports to trade repositories must be submitted in the standardised ISO 20022 XML format — the same format used in MiFIR and SFTR reporting. This replaces the previous CSV-based reporting and required reporting entities to update their systems. The standardisation is intended to improve data quality and reduce reconciliation errors across trade repositories.

 

Unique Product Identifier (UPI)

OTC derivatives that are not admitted to trading or transacted on a trading venue must be identified using a Unique Product Identifier (UPI), issued by the Derivatives Service Bureau and recognised globally. This brings EU reporting in line with international identification standards. Derivatives traded on a trading venue continue to be identified by ISIN.

Unique Trade Identifier (UTI)

Each derivative transaction is identified by a Unique Trade Identifier (UTI) generated by one of the counterparties following the ISO 23897 format. The UTI must be identical in the reports submitted by both counterparties — which means counterparties must agree on UTI generation responsibility before or at the time of trade.

Increased Reporting Fields

The number of reportable fields increased significantly under the new framework. The expanded data set is intended to provide regulators with more granular insight into derivative markets, but it also means more fields to populate accurately and reconcile between counterparties.

FC Reporting on Behalf of NFC-

For OTC derivative contracts between an EU-established FC and an NFC-, the FC is solely responsible and legally liable for reporting on behalf of both counterparties. This shifts operational burden away from the smaller corporate counterparty, though NFC- entities can opt out — but rarely do, as the practical advantage of letting the larger counterparty report is significant.

Errors and Omissions Notification

There is a new requirement for counterparties to notify the relevant national competent authority of significant reporting issues, errors, and omissions. This formalises an obligation that was previously implicit and increases the procedural rigour around reporting quality.

EMIR 3 and the Active Account Requirement

EMIR 3, which entered into force on 24 December 2024, introduced measures to mitigate excessive exposures to third-country central counterparties and to improve the efficiency of EU clearing markets. The most prominent new obligation is the Active Account Requirement (AAR), which requires certain counterparties subject to the relevant EMIR clearing and threshold conditions to maintain active clearing accounts at EU CCPs and to clear a specified portion of their relevant derivative activity through them.

 

The AAR is being implemented through technical standards. The reporting templates and instructions for the AAR reporting obligation under Article 7b of EMIR were developed by ESMA and entered into force in February 2026. EMIR 3 also amended the equivalence provisions in Article 13, with substituted compliance now available only for risk mitigation requirements rather than for clearing or reporting.

The full implementation of EMIR 3 continues to unfold through subsequent technical standards. Corporate investors with material EU CCP exposure should monitor regulatory developments and consult their legal advisers on the specific application to their business.

Risk Mitigation for Non-Cleared OTC Derivatives

OTC derivatives that are not cleared through a central counterparty are subject to risk mitigation requirements: timely confirmation, portfolio reconciliation, portfolio compression where applicable, dispute resolution procedures, and exchange of margin (initial and variation) for in-scope counterparties. The detailed margin requirements have been phased in over time and apply to FCs and NFC+ entities meeting specified thresholds.

For corporate counterparties qualifying as NFC- and using OTC derivatives primarily for hedging, many of the more onerous margin requirements do not apply, but timely confirmation and portfolio reconciliation obligations still need to be addressed. Practical compliance involves having appropriate contractual and operational arrangements with each FC counterparty, agreed dispute resolution procedures, and operational processes for periodic reconciliation.

What Corporate Investors Should Verify

Counterparty Classification

Confirm your classification under EMIR (typically NFC- for most non-financial corporates) and review it periodically. The classification depends on group-level derivative activity above or below defined thresholds, and corporate restructuring, M&A, or growth in derivative activity can change the classification.

Reporting Arrangement

Verify whether your counterparty (the FC) is reporting on your behalf, or whether you have opted out. If your counterparty reports, confirm that they are receiving accurate trade data from you for inclusion in reports — even when the FC reports, the underlying data they use comes from your records.

ISDA and Documentation

Review the contractual and collateral documentation applicable to each counterparty, which may include an ISDA Master Agreement, Credit Support Annex and EMIR-related provisions. The documentation should be consistent with the applicable regulatory requirements and the transaction structure.

LEI Maintenance

Both counterparties to a reportable derivative must have a valid Legal Entity Identifier (LEI), and the LEI must be renewed regularly. Lapsed LEIs cause reporting failures. Corporate treasuries should maintain LEI renewal as a documented operational process.

Internal Controls

For NFC counterparties subject to portfolio reconciliation and dispute resolution requirements, maintain documented processes and audit trails. Any statutory-audit requirement should be assessed under the applicable national law and the circumstances of the entity.

How OTC Derivatives Fit Into Investment Portfolios

Beyond corporate treasury hedging, OTC derivatives appear in investment portfolios in specific contexts. Portfolio managers may use OTC structured products, total return swaps, or bilateral options for specific exposures that exchange-traded products do not provide. These uses are subject to the applicable  applicable regulatory, product-governance, client-classification and service requirements.

.

Skanestas may include OTC derivatives within the permitted instrument universe
of certain portfolio management services, alongside exchange-traded derivatives
and repurchase agreements. The use of OTC derivatives is subject to the firm’s
documented investment process, applicable EMIR-related compliance obligations,
and the terms governing the relevant client relationship. Their availability and use depend on the applicable service, client classification, strategy mandate and regulatory requirements and do not imply that any particular instrument or strategy is appropriate for a client.

Common Misconceptions

‘EMIR only applies to large institutions’

False. EMIR reporting applies to counterparties to reportable derivative contracts, including small corporates. The exact obligations vary by classification, but reporting and other EMIR requirements depend on the transaction and counterparty classification,  and corporates classified as NFC- still have important responsibilities even though FC counterparties typically report on their behalf.

‘If my counterparty reports, I have nothing to do’

False. Even when the FC reports, the underlying data quality depends on the corporate counterparty providing accurate trade information. Corporates retain responsibility for the accuracy of trade data on their side, for LEI maintenance, for confirmation procedures, and for reconciliation.

‘EMIR rules do not apply to FX forwards’

Generally false. FX forwards used for hedging are typically subject to EMIR reporting requirements. The treatment of a particular FX contract depends on whether it falls within the EMIR definition of a derivative; qualifying spot FX transactions are treated differently from FX forwards. Some jurisdictions have specific exemptions for very short-dated FX (rolling spot), but most material FX forwards are reportable.

‘Brexit eliminated UK-EU EMIR alignment’

Partially. The UK has retained EMIR (UK EMIR) with broadly similar structure but increasingly divergent specifics, particularly under EMIR 3 which the UK has not yet adopted equivalently. Cross-border counterparty arrangements need to consider both regimes where applicable.

 

FAQ

Are exchange-traded derivatives subject to EMIR?

Yes, EMIR reporting applies to both OTC and exchange-traded derivatives, though the operational details and clearing obligations differ. Exchange-traded derivatives are typically already cleared through CCPs, so the central clearing obligation is met by the trading venue’s clearing arrangement.

What is a Trade Repository?

A Trade Repository (TR) is a registered entity that centrally collects and maintains the records of derivative contracts. EU trade repositories must be registered with ESMA, and third-country trade repositories providing services to EU entities must be recognized by ESMA.

Counterparties (or those reporting on their behalf) must select a TR and submit reports there.

How long must EMIR records be kept?

EMIR requires counterparties to keep records of any derivative contract they have concluded, modified, or terminated for at least five years following the termination of the contract.

What happens if I fail to meet EMIR obligations?

EMIR violations are subject to administrative penalties imposed by the relevant national competent authority. Penalties vary by jurisdiction and severity. Significant or systematic non-compliance can also affect counterparty relationships, as FCs are increasingly cautious about trading with counterparties whose compliance is uncertain.

Conclusion

OTC derivatives are essential for many corporate treasuries and have specific applications in professional investment portfolios. The EMIR framework, as updated by Refit and EMIR 3, requires careful operational discipline — the framework is comprehensive, the technical standards are detailed, and the consequences of non-compliance are real. For corporate investors, the practical objective is documented compliance with classification, reporting, and risk-mitigation requirements; for investment portfolios using OTC derivatives, the framework is part of the broader regulatory environment within which professional managers operate. As always, this article is informational and does not replace legal or regulatory advice tailored to specific circumstances.

 

About this article: This material is published for general informational purposes by Skanestas Investments Limited, a Cyprus Investment Firm authorised and regulated by the Cyprus Securities and Exchange Commission under licence CIF251/14. The content reflects general industry practice and information available as at the date of publication may be updated from time to time without notice. The article does not establish a client relationship and does not replace the formal contractual, regulatory and client documents  that govern any portfolio management or brokerage relationship with the firm. Risk warning: Investing in financial instruments carries risk and the value of investments may rise or fall. You may receive back less than the amount invested. Please review the firm’s Risk Disclosure Statement and other regulatory documents before engaging with any service. The information provided is general in nature and should not be understood as a statement of the services provided by the firm. Last updated: 2026.